Log In / Sign Up

HR 6832

  • House Bill
  • 117th Congress
  • Introduced in House Feb 25, 2022
  • House
  • Senate
  • Governor

To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

View Latest Bill Text
Sign In to Follow

Abstract

Bill Sponsors (7)

Michael Cloud

  • Republican
  • Representative
  • TX-27
Primary

Daniel Webster

  • Republican
  • Representative
  • FL-11
Cosponsor

Andy Biggs

  • Republican
  • Representative
  • AZ-5
Cosponsor

Mary Miller

  • Republican
  • Representative
  • IL-15
Cosponsor

Tom Tiffany

  • Republican
  • Representative
  • WI-7
Cosponsor

Byron Donalds

  • Republican
  • Representative
  • FL-19
Cosponsor

Mo Brooks

  • Republican
Cosponsor

Votes

No votes to display

Actions

Feb 28, 2022

House

Referred to the Subcommittee on Health.

Feb 25, 2022

House

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

US Congress

Introduced in House

Bill Text

Bill Text Versions Format
Introduced in House PDF XML

Related Documents

Document Format
No related documents.

Sources

Data on Open States is updated periodically throughout the day from the official website of the US Congress.

If you notice any inconsistencies with these official sources, feel free to file an issue.